$NVCR NovoCure Ltd Insider Trading Week 35/2019
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NovoCure Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NovoCure Ltd in week 35/2019.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 21.15 | 30,414 | 643,256 | 86,513 | |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 7.15 | 56,874 | 406,649 | 97,799 | |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 6.72 | 11,632 | 78,167 | 0 | |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 6.72 | 59,520 | 399,974 | 0 | |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.86 | 1,200 | 107,828 | 53,900 | 55.1 K to 53.9 K (-2.18 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.86 | 2,900 | 257,703 | 55,100 | 58 K to 55.1 K (-5.00 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.18 | 14,888 | 1,312,794 | 58,000 | 72.9 K to 58 K (-20.43 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.86 | 11,426 | 992,440 | 72,888 | 84.3 K to 72.9 K (-13.55 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 21.15 | 30,414 | 643,256 | 84,314 | 53.9 K to 84.3 K (+56.43 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.87 | 4,031 | 362,262 | 53,900 | 57.9 K to 53.9 K (-6.96 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.97 | 7,869 | 700,129 | 57,931 | 65.8 K to 57.9 K (-11.96 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.22 | 24,083 | 2,124,482 | 65,800 | 89.9 K to 65.8 K (-26.79 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.95 | 20,891 | 1,816,556 | 89,883 | 110.8 K to 89.9 K (-18.86 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 7.15 | 56,874 | 406,649 | 110,774 | 53.9 K to 110.8 K (+105.52 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.97 | 400 | 35,988 | 53,900 | 54.3 K to 53.9 K (-0.74 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.94 | 929 | 82,622 | 54,300 | 55.2 K to 54.3 K (-1.68 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.19 | 6,065 | 534,897 | 55,229 | 61.3 K to 55.2 K (-9.89 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.88 | 4,238 | 368,206 | 61,294 | 65.5 K to 61.3 K (-6.47 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 6.72 | 11,632 | 78,167 | 65,532 | 53.9 K to 65.5 K (+21.58 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.90 | 2,300 | 206,759 | 53,900 | 56.2 K to 53.9 K (-4.09 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.82 | 6,616 | 587,620 | 56,200 | 62.8 K to 56.2 K (-10.53 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.17 | 28,340 | 2,498,766 | 62,816 | 91.2 K to 62.8 K (-31.09 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.85 | 22,264 | 1,933,539 | 91,156 | 113.4 K to 91.2 K (-19.63 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 6.72 | 59,520 | 399,974 | 113,420 | 53.9 K to 113.4 K (+110.43 %) |
Sep 03 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 92.00 | 500 | 46,000 | 134,601 | 135.1 K to 134.6 K (-0.37 %) |
Sep 03 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 91.60 | 65,768 | 6,024,612 | 135,101 | 200.9 K to 135.1 K (-32.74 %) |
Sep 03 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 90.58 | 57,913 | 5,245,586 | 200,869 | 258.8 K to 200.9 K (-22.38 %) |
Sep 03 2019 | NVCR | NovoCure Ltd | PHILLIPS CHARLES G III | Director | Option Exercise | M | 6.72 | 22,000 | 147,840 | 40,607 | |
Sep 03 2019 | NVCR | NovoCure Ltd | PHILLIPS CHARLES G III | Director | Sell | S | 92.10 | 400 | 36,839 | 9,504 | 9.9 K to 9.5 K (-4.04 %) |
Sep 03 2019 | NVCR | NovoCure Ltd | PHILLIPS CHARLES G III | Director | Sell | S | 91.46 | 12,908 | 1,180,540 | 9,904 | 22.8 K to 9.9 K (-56.58 %) |
Sep 03 2019 | NVCR | NovoCure Ltd | PHILLIPS CHARLES G III | Director | Sell | S | 90.63 | 8,692 | 787,739 | 22,812 | 31.5 K to 22.8 K (-27.59 %) |
Sep 03 2019 | NVCR | NovoCure Ltd | PHILLIPS CHARLES G III | Director | Buy | M | 6.72 | 22,000 | 147,840 | 31,504 | 9.5 K to 31.5 K (+231.48 %) |
Sep 03 2019 | NVCR | NovoCure Ltd | VERNON W ANTHONY | Director | Sell | S | 91.03 | 100,000 | 9,103,100 | 158,589 | 258.6 K to 158.6 K (-38.67 %) |